Immune checkpoint inhibitors in people living with hiv/aids: Facts and controversies

Abstract

Immune checkpoint inhibitors (ICIs) are reshaping the landscape of cancer treatment, re-defining the prognosis of several tumors. They act by restoring the cytotoxic activity of tumor‐spe-cific T lymphocytes that are in a condition of immune exhaustion. The same condition has been widely described in chronic HIV infection. In this review, we dissect the role of ICIs in people living with HIV/AIDS (PLWHIV). First, we provide an overview of the immunologic scenario. Second, we discuss the possible use of ICIs as adjuvant treatment of HIV to achieve elimination of the viral reservoir. Third, we examine the influence of HIV infection on ICI safety and effectiveness. Finally, we describe how the administration of ICIs impacts opportunistic infections.